CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

D
David Rosmarin

Primary Investigator

Enrolling By Invitation
12 years - 15 years
All
Phase N/A
10 participants needed
4 Locations

Brief description of study

What is the purpose of this study?
The purpose of this registry study is to learn more about AD, how doctors treat AD in adolescent population, how well medications and other treatments work, the safety of those treatments, and to improve the care and outcomes of people with AD. Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of AD to support ongoing risk-benefit evaluation by drug manufacturers and regulators. Further, data collected will inform clinical decision making by patients and treating providers. Approximately 1500 males and females ages 12 to 15 years of age with a diagnosis of AD in North America and some European countries are expected to participate in this registry. 
 
THIS STUDY IS ENROLLING BY INVITATION ONLY - Adolescent patients with Atopic Dermatitis under the care of a dermatology provider will be identified and contacted about study participation.

Detailed description of study

What will happen during the study?
  • Participants will be asked to complete CorEvitas Registry forms during their regularly scheduled visits with their doctor. They will be providing information about themselves and their AD condition through the forms.
    Standardized data collection will occur, including validated instruments for patient-reported outcomes (PROs) and clinician-reported outcomes (ClinROs), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.
  • This provides an opportunity to evaluate other aspects of the disease and its treatment, including but not limited to clinical and drug cost-effectiveness, health care resource utilization, and subject adherence.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Atopic Dermatitis
  • Age: 12 years - 15 years
  • Gender: All

Inclusion Criteria:

  • To be eligible to participate in this registry, an individual must meet all the following criteria:
    1. Has been diagnosed with moderate to severe atopic dermatitis by a dermatologist or a qualified dermatology practitioner.
    2. Is 12 - 15 years of age at the time of enrollment.
    3. Meets one of the following conditions at the time of enrollment:

      1. Has started taking a new Enrollment Eligible Medication within 6 months prior to the Enrollment visit. A new medication is a medication that the subject has never taken before.

        OR

      2. Is prescribed a new Enrollment Eligible Medication at the Enrollment visit. A new medication is a medication that the subject has never taken before.

        Exclusion Criteria:

        An individual who meets any of the following criteria will be excluded from participation in the registry:

  1. Is participating or planning to participate in a blinded clinical trial for an AD drug.

Updated on 14 Oct 2025. Study ID: DERM-COREVITAS-AD-555, 24094
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

This study is accepting only persons who receive care at a certain clinic or doctor or who are part of an invited group. Questions about this study can be directed to the study team listed in the description or contact your doctor to see if you are eligible.

Accepting Referrals by Invitation Only